Comparision of Pharmacokinetics(PK) and Pharmacodynamics(PD) of Biocon Insulin R and Humulin® R

Phase 1 Completed 42 enrolled Biocon Limited Profil Institut für Stoffwechselforschung GmbH · collab

RandomizedCrossoverDouble-blindOther

Summary

Single-centre, randomised, double-blind, single dose, two-treatment, two-period, two sequence, crossover,12-hour euglycaemic glucose clamp trial in healthy subjects

Timeline

Start: 2019-06-18
Primary completion: 2019-09-15
Completion: 2019-09-20

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Biocon Insulin R	Protein / enzyme biologic	0.3 iu/kg	Subcutaneous
Comparator	Insulin	Protein / enzyme biologic	0.3 iu/kg	Subcutaneous

Indications

No indication recorded.